论文部分内容阅读
目的:观察辛伐他汀对肥胖伴高脂血症患者炎症状态及氧化应激水平的影响。方法:选择我院39例肥胖伴高脂血症的患者为试验组,服用辛伐他汀8周;并选择20例健康志愿者设为健康对照组,不作任何干预。所有研究对象在对照组服药前后检测血脂、血清C反应蛋白(CRP)、丙二醛(MDA)、过氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)。结果:治疗前与健康对照组比较,试验组患者血浆中炎症指标血浆CRP水平明显升高,氧化应激指标中MDA明显升高,SOD水平、GSH-Px活性明显降低,差异均有统计学意义(P<0.05)。服用辛伐他汀8周后,试验组患者较治疗前血清CRP、MDA明显降低,SOD水平、GSH-Px活性明显回升,差异亦有统计学意义(P<0.05)。结论:辛伐他汀可通过抗炎和抗氧化应激机制对肥胖伴高脂血症患者起到保护作用。
Objective: To observe the effect of simvastatin on inflammatory status and oxidative stress in obese patients with hyperlipidemia. Methods: Thirty-nine patients with obesity and hyperlipidemia in our hospital were selected as experimental group and simvastatin for 8 weeks. 20 healthy volunteers were selected as healthy control group without any intervention. All subjects were tested for serum lipids, serum C-reactive protein (CRP), malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) before and after taking the medicine in the control group. Results: Compared with healthy control group before treatment, plasma CRP levels in plasma of patients in experimental group were significantly increased, MDA in oxidative stress index was significantly increased, SOD activity and GSH-Px activity were significantly decreased, the difference was statistically significant (P <0.05). After 8 weeks of taking simvastatin, the serum CRP and MDA, the level of SOD and the activity of GSH-Px in the test group were significantly higher than those before treatment (P <0.05). Conclusion: Simvastatin can protect obese patients with hyperlipidemia through anti-inflammatory and anti-oxidative stress mechanisms.